ERBB2 and breast cancer: In this study, we combined bioinformatics, retrospective study and cell experiment to investigate the potential predictive value of ATRX in first-line drugs resistance of HER2-/HR+ BC patients and tried to explore the mechanism preliminary so as to provide therapeutic strategy precisely for clinicians.